|
|
|
|
|
|
Sponsored by: |
SGX Pharmaceuticals, Inc. |
Information provided by: | SGX Pharmaceuticals, Inc. |
ClinicalTrials.gov Identifier: | NCT00104286 |
This is a phase I, single-arm, open-label, single-center study to establish the recommended infusion schedule for Troxatyl™ administered as a continuous infusion for 2-5 days to subjects with solid tumors.
Condition | Intervention | Phase |
Neoplasms |
Drug: Troxatyl™ (Cytotoxic Chemotherapeutic) |
Phase I Phase II |
MedlinePlus related topics: | Cancer |
ChemIDplus related topics: | Troxacitabine |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | An Open-Label, Single-Arm, Phase I Study of Troxatyl™ (Troxacitabine) Administered by Continuous Infusion in Subjects With an Advanced Solid Malignancy |
Estimated Enrollment: | 50 |
Study Start Date: | January 2003 |
Estimated Study Completion Date: | November 2005 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | SPD758-109 |
First Received: | February 24, 2005 |
Last Updated: | November 1, 2006 |
ClinicalTrials.gov Identifier: | NCT00104286 |
Health Authority: | United States: Food and Drug Administration |
|
|
|